Dermatomyositis with Diffuse Large B Cell Lymphoma

Eun Jung Jang; Hyoun Ah Kim; Jun Mo Sung; Jin Woo Lee; Eui Kyung Hwang; Hugh Chul Kim; Jae Ho Han; Chang Hee Suh

doi:10.4078/jkra.2009.16.4.323

Journal List > J Korean Rheum Assoc > v.16(4) > 1003693

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jang, Kim, Sung, Lee, Hwang, Kim, Han, and Suh: Dermatomyositis with Diffuse Large B Cell Lymphoma

Original Article

J Korean Rheum Assoc 2009;16(4):323-327.

Published online: 20 January 2009

DOI: https://doi.org/10.4078/jkra.2009.16.4.323

Dermatomyositis with Diffuse Large B Cell Lymphoma

Eun Jung Jang¹, Hyoun Ah Kim¹, Jun Mo Sung¹, Jin Woo Lee¹, Eui Kyung Hwang¹, Hugh Chul Kim², Jae Ho Han³, Chang Hee Suh¹

¹Department of Allergy and Rheumatology, Ajou University School of Medicine, Suwon, Korea

²Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea

³Department of Pathology, Ajou University School of Medicine, Suwon, Korea

Received 15 July 2009 Revised 2 September 2009 Accepted 2 September 2009

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Dermatomyositis (DM) is a rare and idiopathic inflammatory myopathy with characteristic cutaneous manifestations. There is a well-recognized association between DM and cancers. In Korea, several DM cases have been reported to be associated with stomach cancer, breast cancer, acute lymphoblastic leukemia, lung cancer, and tonsil cancer. However, an association between DM and lymphoma in Korea has not been reported up to now. We report a case of DM who developed diffuse large B-cell lymphoma 1 year and 8 months later.

Keywords: Dermatomyositis, Diffuse large B-cell lymphoma, Cancer

References

1. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991; 325:1487–98.

2. Stertz G, Polymyositis. Berl Kin Wochenschr. 1916; 53:489.

3. Kim SM, Choi YH, Oh MD, Nam TS, Chung MH, Rai HJ, et al. A clinical analysis of 100 patients with dermatomyositis – polymyositis. Korean J Med. 1990; 39:812–23.

4. Lee SW, Jung SY, Park MC, Park YB, Lee SK. Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J. 2006; 47:519–23.

5. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med. 1976; 84:68–76.

6. Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005; 1051:64–71.

7. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC. Update on idiopathic inflammatory myopathy. Autoimmunity. 2006; 39:161–70.

8. Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008; 7:352–8.

9. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol. 2001; 144:825–31.

10. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002; 41:729–34.

11. Carsons S. The association of malignancy with rheumatic and connective tissue disease. Semin Oncol. 1997; 24:360–72.

12. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis; a population based study. Lancet. 2001; 357:96–100.

13. Kojima M, Itoh H, Shimizu K, Saruki N, Murayama K, Higuchi K, et al. Malignant Lymphoma in Patients with Systemic Rheumatic Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis): A Clinicopathologic Study of 24 Japanese Cases. Int J Surg Pathol. 2006; 14:43–8.

14. Chung L, Genovese MC, Fiorentino DF. A pilot Trial of Rituximab in the Treatment of Patients With Dermatomyositis. Arch Dermatol. 2007; 143:763–7.

Fig. 1.

Cervical lymph node biopsy. (A) Extensive replacement of normal architecture by neoplastic centrocytes and centroblasts (H&E stain, ×100), (B) Centroblastic lymphoma shows neoplastic cells that are much larger than lymphocytes (H&E stain, ×400), (C) The tumor cells are positive for CD20 stain (Immunohistochemical stain with anti-CD20 antibody, ×400)

Fig. 2.

Positron emission tomography. (A) Probably multiple malignant lesions on subcutaneous nodules, abdominal lymph nodes (LNs), both axillary LNs and inguinal LNs and bone involvements on T5 and C5 were shown. (B) There was no significant abnormal FDG uptake to suggest malignancy. Benign reactive LNs uptake in right lower paratracheal and both hilar space was shown.

TOOLS

Similar articles